- 13 628
- 3 698 496
VJHemOnc - Video Journal of Hematology & HemOnc
United Kingdom
Приєднався 11 лют 2015
The Video Journal of Hematology & Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers.
Our goal is to expedite learning through the sharing of new data and expert opinion, and to rapidly disseminate the latest news and information to healthcare professionals, worldwide, on a range of innovative digital media - including video and blog formats.
VJHemOnc content is led by an editorial board of highly respected thought leaders with a combined expertise that spans the spectrum of hematological cancers. All content is created and published under the guidance of this board of world-leading experts.
Our goal is to expedite learning through the sharing of new data and expert opinion, and to rapidly disseminate the latest news and information to healthcare professionals, worldwide, on a range of innovative digital media - including video and blog formats.
VJHemOnc content is led by an editorial board of highly respected thought leaders with a combined expertise that spans the spectrum of hematological cancers. All content is created and published under the guidance of this board of world-leading experts.
An overview of platelet dysfunction in patients with myeloproliferative neoplasms
Chloe James, MD, PhD, University Hospital of Bordeaux, Bordeaux, France, summarizes recent advancements in the understanding of platelet dysfunction in myeloproliferative neoplasms (MPNs). Thrombotic events occur more frequently in patients with MPNs than healthy controls, and studies have shown that this could be due to platelet hyperactivation. Additionally, other studies demonstrated that JAK2-mutated platelets can activate neutrophils, which form neutrophil extracellular traps (NETs) and can promote thrombosis. Administration of aspirin, an antiplatelet agent, is therefore beneficial in reducing thrombosis for patients with MPNs by reducing both platelet and neutrophil activation. This interview took place at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Переглядів: 1
Відео
Cytometry versus morphology in the monitoring of AML
Переглядів 2
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential of replacing morphology with flow cytometry for monitoring patients with acute myeloid leukemia (AML). While flow cytometry is highly sensitive and specific for detecting residual AML, it has limitations. Therefore, Dr Loghavi recommends using it in combination with morphology for optimal ...
Oral azacitidine maintenance in AML with MDS-related changes: insights from QUAZAR AML-001
Переглядів 4
Maria Teresa Voso, MD, University Tor Vergata, Rome, Italy, discusses a sub-analysis of the QUAZAR AML-001 (NCT01757535) study, which examined oral azacitidine maintenance therapy for patients with acute myeloid leukemia (AML) with myelodysplastic syndrome (MDS)-related changes. The study found that azacitidine significantly improved relapse-free survival (RFS) compared to placebo, suggesting i...
An overview of the management of patients with R/R Waldenström’s macroglobulinemia
Переглядів 32 години тому
Ramón Garcia Sanz, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain, discusses the management of patients with relapsed/refractory (R/R) Waldenström’s macroglobulinemia (WM). These patients can be divided into two groups: those who relapse after chemoimmunotherapy and those who are resistant or who relapse after BTK inhibitors (BTKis). For the former, a switch to BTKis, such as ib...
Insights into the uses of ibrutinib for patients with Waldenström’s macroglobulinemia
Переглядів 72 години тому
Ramón Garcia Sanz, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain, discusses the use of ibrutinib, a BTK inhibitor, in the treatment of patients with Waldenström's macroglobulinemia (WM). Ibrutinib has shown the best response rates in WM after chemoimmunotherapy and can be used as a first-line treatment when chemoimmunotherapy is not manageable. It does, however, have side effec...
Results from a study on the combination of sonrotoclax and zanubrutinib in R/R MCL
Переглядів 62 години тому
Ramón Garcia Sanz, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain, presents results from the ongoing Phase I study (NCT04277637) of the combination of sonrotoclax, a BCL2 targeted agent, and zanubrutinib, a BTK inhibitor, for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This oral-based therapy was administered in different dosages to 40 patients and led to...
Reducing CRS following epcoritamab in R/R FL: insights from an optimization cohort of EPCORE NHL-1
Переглядів 33 години тому
Umberto Vitolo, MD, Candiolo Cancer Institute, Turin, Italy, discusses an optimization cohort from the EPCORE NHL-1 trial (NCT03625037), investigating epcoritamab in relapsed/refractory (R/R) follicular lymphoma (FL). Additional measures, including a second intermediate dose on day 15 and dexamethasone prophylaxis, reduced the incidence and severity of cytokine release syndrome (CRS) while main...
Mitigating infection risks in patients with CLL
Переглядів 93 години тому
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses infection risks in patients with chronic lymphocytic leukemia (CLL). Efforts are underway to use a machine learning algorithm to predict high-risk patients. Current strategies for mitigating infections include vaccinations and intravenous immunoglobulins. Dr Brown also notes that CAR T-cell treatment may exacerbate hyp...
The ALPINE trial shows improved outcomes with zanubrutinib versus ibrutinib in R/R CLL
Переглядів 73 години тому
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the ALPINE trial (NCT03734016), comparing zanubrutinib to ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The trial demonstrated an improved overall response rate (ORR) and progression-free survival (PFS) in the zanubrutinib arm, especially in high-risk patients with 17p deletio...
Real-world dose de-escalation of teclistamab in patients with R/R myeloma
Переглядів 53 години тому
Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses real-world dose de-escalation of teclistamab in patients with relapsed/refractory (R/R) multiple myeloma (MM). While the MajesTEC-1 trial (NCT04557098) demonstrated the efficacy of teclistamab, it also highlighted a high risk of infection. Patients at Dr Usmani’s center who underwent dose de-escalation a...
The addition of blinatumomab to prephase and consolidation therapy in adult B-ALL
Переглядів 43 години тому
Anita Rijneveld, MD, Erasmus MC, Rotterdam, Netherlands, discusses the addition of blinatumomab to prephase and consolidation therapy in adult B-cell acute lymphoblastic leukemia (B-ALL). The study showed high complete remission (CR) rates, including substantial measurable residual disease (MRD) negativity. The approach proved safe, with minimal high-grade cytokine release syndrome (CRS) and ne...
The real world utilization of MRD in myeloma across Europe
Переглядів 43 години тому
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the real-world utilization of measurable residual disease (MRD) in myeloma across Europe. He highlights MRD's role in defining high-quality complete remissions (CRs) and notes that the PERSEUS trial (NCT03710603) used MRD to guide treatment decisions. If these treatments are approved in Europe, MRD monitoring should become stan...
The use of targeted drug therapy for aggressive lymphoma
Переглядів 103 години тому
Mariana Bastos, MD, PhD, Gregorio Marañón University General Hospital, Madrid, Spain, discusses advancements in targeted therapies for aggressive lymphoma. She highlights early-line treatments combining novel cereblon E3 ligase modulators (CELMoDs) or atezolizumab with the R-CHOP regimen. In the relapsed/refractory (R/R) setting, she notes the combinations of glofitamab with a novel CD19/4-1BB ...
Unmet needs in front-line therapy for patients with FLT3-mutated AML
Переглядів 63 години тому
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the unmet needs in front-line therapies for patients with FLT3-mutated acute myeloid leukemia (AML). Key areas for improvement include increasing remission rates and facilitating transplants for younger patients. For older patients, the standard treatments-azacitidine or decitabine plus venetoclax-are less effective agai...
The main goals of therapy in AL amyloidosis
Переглядів 54 години тому
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, discusses the primary goals of therapy in light chain (AL) amyloidosis. The main objective is to improve survival by achieving a profound hematologic response. Complete response (CR) and very good partial response (VGPR) are key targets, as they are associated with better survival outcomes. The role of anti-amyloid ...
Predictors of early mortality in patients with wild-type transthyretin amyloidosis
Переглядів 65 годин тому
Predictors of early mortality in patients with wild-type transthyretin amyloidosis
Results of the MoRBiDA trial: 18F-PET for the detection of cardiac involvement in AL amyloidosis
Переглядів 55 годин тому
Results of the MoRBiDA trial: 18F-PET for the detection of cardiac involvement in AL amyloidosis
Efficacy of diflunisal for hereditary transthyretin amyloidosis: data from the SveATTR registry
Переглядів 35 годин тому
Efficacy of diflunisal for hereditary transthyretin amyloidosis: data from the SveATTR registry
Real-world survival in patients with mixed phenotype ATTR-CM treated with tafamidis
Переглядів 65 годин тому
Real-world survival in patients with mixed phenotype ATTR-CM treated with tafamidis
An overview of CAR T-cell therapies in the treatment of patients with MCL
Переглядів 8222 години тому
An overview of CAR T-cell therapies in the treatment of patients with MCL
The effectiveness of ibrutinib flexible dosing regimens on TTNT in CLL/SLL
Переглядів 2923 години тому
The effectiveness of ibrutinib flexible dosing regimens on TTNT in CLL/SLL
An overview of the main challenges to prolonging remission in AML
Переглядів 4423 години тому
An overview of the main challenges to prolonging remission in AML
Improving transplantation rates by increasing CR in AML
Переглядів 7123 години тому
Improving transplantation rates by increasing CR in AML
Overcoming the challenges in prolonging remission in AML
Переглядів 51День тому
Overcoming the challenges in prolonging remission in AML
An overview of the different modalities used to assess MRD in AML
Переглядів 13День тому
An overview of the different modalities used to assess MRD in AML
Insights into the influence of cardiovascular toxicity risk on treatment selection in CLL
Переглядів 6День тому
Insights into the influence of cardiovascular toxicity risk on treatment selection in CLL
Insights into the future of the CLL treatment landscape
Переглядів 26День тому
Insights into the future of the CLL treatment landscape
Targeting MCL1-mediated survival to overcome HMA resistance in CMML
Переглядів 334 години тому
Targeting MCL1-mediated survival to overcome HMA resistance in CMML
A Phase I/II trial of seclidemstat in combination with azacitidine for patients with MDS and CMML
Переглядів 144 години тому
A Phase I/II trial of seclidemstat in combination with azacitidine for patients with MDS and CMML
An update on the COBRA trial: PET-response adapted treatment with brentuximab vedotin for HL
Переглядів 574 години тому
An update on the COBRA trial: PET-response adapted treatment with brentuximab vedotin for HL
Dr. Shah is the future of oncology
In other words, using mRNA to deliver DNA editing technology. Is this done through CRISPR cas-9? This is very interesting! Thank you!
I'm going to enter a clinical trial with vibecotamab in about 3-4 days. After four remissions and two stem cell transplants, I would really like to find something that gets me out of the 'medical merry-go-round. . I'm 77.
Merci Pr MOHTY
Excellent
Excellent
Excellent
Stay up-to-date with the latest in lymphoma by visiting: www.vjhemonc.com/subject/lymphoma/
For the latest updates in immuno-oncology, check out our site: 👉www.vjhemonc.com/field/immuno-oncology/
Check out the latest in rare diseases, including smoldering myeloma, rare lymphomas, rare MPNs, and more, on our site: 👉www.vjhemonc.com/subject/rare-diseases/
Discover the latest updates in ALL by visiting our site: 👉www.vjhemonc.com/subject/acute-lymphoblastic-leukemia/
Visit our site and explore the latest updates in AML with our expert interviews, roundtable discussions, features, and more: www.vjhemonc.com/subject/acute-myeloid-leukemia/
Stay updated with the latest in hematology with our feature articles! For more, visit: 👉www.vjhemonc.com/features/
Check out more transplantation content here: www.vjhemonc.com/field/transplantation/?transplantationtopic
Explore more content on lymphoma on our site: www.vjhemonc.com/subject/lymphoma/?lymphomachannel
Check out our MDS Channel to stay updated with the latest in MDS: 👉www.vjhemonc.com/subject/myelodysplastic-syndromes/
Find more content on ALL here: www.vjhemonc.com/subject/acute-lymphoblastic-leukemia/?allchannel
For the latest updates in CLL, check out our site: www.vjhemonc.com/subject/chronic-lymphocytic-leukemia/
Click here to find more content on stem cell transplantation: www.vjhemonc.com/field/transplantation/?transplantationtopic
Check out the latest in multiple myeloma on our website: www.vjhemonc.com/subject/multiple-myeloma/?myelomachannel
Check out our Multiple Myeloma Channel for all the latest in this space: 👉 www.vjhemonc.com/subject/multiple-myeloma/
Check out our website for more lymphoma content: www.vjhemonc.com/subject/lymphoma/?lymphomachannel
For the latest CAR-T & cellular therapy updates, visit our site: 👉www.vjhemonc.com/field/car-t-cellular-therapy/
For more content on stem cell transplantation check out our website: www.vjhemonc.com/field/transplantation/?transplantationtopic
For more content on MRD click here: www.vjhemonc.com/field/mrd/?mrdtopic
For more AML content check out our site 👉 www.vjhemonc.com/subject/acute-myeloid-leukemia/?amlchannel
For more CAR-T & Cellular Therapy content check out our site 👉 www.vjhemonc.com/field/car-t-cellular-therapy/
Congratulations! This is great news for AML patients.